[Activity Repor] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)
date : 11/2/2022
Tags: AMR
![[Activity Repor] The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery releases recommendations entitled, “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.” (August 2, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/AMRalliance-logo-11-26.jpg)
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery, for which AMR Alliance Japan (Secretariat: HGPI) is a cooperating member, has released recommendations on “The Need for a System that Allows Continued Research and Development of Therapeutic Agents, Vaccines, and Tests for Pandemics and Silent Pandemics: Background and Objectives.”
The recommendation can be found here.
*Available Only in Japanese
■The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery
The Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery is comprised of The Japanese Society of Chemotherapy, The Japanese Association for Infectious Disease, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society for Bacteriology, The Pharmaceutical Society of Japan, and The Japanese Society of Veterinary Science. It investigates the promotion of infectious disease therapy and drug therapy from a medical perspective.
■AMR Alliance Japan
AMR Alliance Japan AMR was established in November 2018 as a multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of August 2022, its members include MSD K.K., “Kodomo to Iryo” Project, Shionogi & Co., Ltd., Sumitomo-Pharma Co., Ltd., The Japanese Society of Antimicrobials for Animals, NISSUI Pharmaceutical Co., Ltd., Nippon Becton Dickson Co., Ltd., The Japan Medical Association, The Japanese Society for Medical Mycology, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Chemotherapy, The Japanese Society for Infection Prevention and Control, The Japanese Association for Infectious Diseases, The Japanese Society for Pediatric Infectious Diseases, The Japan Pharmaceutical Manufacturers Association, The Japanese Society of Therapeutic Drug Monitoring, The Japanese Society of Hospital Pharmacists, The Pharmaceutical Society of Japan; The Japan Pharmaceutical Association, The Japanese Society for Clinical Microbiology, bioMérieux Japan Ltd., Himeji City, Pfizer Japan Inc., and Meiji Seika Pharma Co., Ltd. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
日本語
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Establishing an Integrated Care System for Pain from the Perspectives of People with Lived Experience (March 29, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] Participation in an International Survey on Brain Health for Young People “The Next Generation (NextGen) Brain Health Research Program” (July 1, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Japanese Version Release] “Call for Actionable Steps in Response to the Rising Threat of Antimicrobial Resistance (AMR)” (July 3, 2024)
Featured Posts
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)
-
2024-07-17
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Towards Overcoming Kidney Disease: Strengthening Measures Against CKD” (June 7, 2024)
-
2024-07-18
[Registration Open] (Hybrid Format) Kidney Disease Control Promotion Project Public Symposium “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” (August 28, 2024)
-
2024-07-22
[HGPI Policy Column] No. 44 — From the Planetary Health Policy Project, Part 9 “Connecting Climate Minds: the Intersection of Climate Change and Mental Health”
-
2024-07-23
[Registration Open] (Webinar) HGPI Special Seminar “The Emerging Threat of Antifungal Resistance — Considering Infectious Diseases Caused by Mold and Measures to Combat Drug Resistance” (August 23, 2024)